JP2010520284A5 - - Google Patents

Download PDF

Info

Publication number
JP2010520284A5
JP2010520284A5 JP2009552711A JP2009552711A JP2010520284A5 JP 2010520284 A5 JP2010520284 A5 JP 2010520284A5 JP 2009552711 A JP2009552711 A JP 2009552711A JP 2009552711 A JP2009552711 A JP 2009552711A JP 2010520284 A5 JP2010520284 A5 JP 2010520284A5
Authority
JP
Japan
Prior art keywords
virus
pharmaceutical composition
poly
tumor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009552711A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010520284A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/002874 external-priority patent/WO2008109083A2/en
Publication of JP2010520284A publication Critical patent/JP2010520284A/ja
Publication of JP2010520284A5 publication Critical patent/JP2010520284A5/ja
Pending legal-status Critical Current

Links

JP2009552711A 2007-03-05 2008-03-05 Toll様受容体3(TLR3)の限定アゴニスト Pending JP2010520284A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90479207P 2007-03-05 2007-03-05
PCT/US2008/002874 WO2008109083A2 (en) 2007-03-05 2008-03-05 Restrictive agonist of toll-like receptor 3 (tlr3)

Publications (2)

Publication Number Publication Date
JP2010520284A JP2010520284A (ja) 2010-06-10
JP2010520284A5 true JP2010520284A5 (enExample) 2011-06-02

Family

ID=39738981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009552711A Pending JP2010520284A (ja) 2007-03-05 2008-03-05 Toll様受容体3(TLR3)の限定アゴニスト

Country Status (11)

Country Link
US (1) US20100183638A1 (enExample)
EP (1) EP2134172A4 (enExample)
JP (1) JP2010520284A (enExample)
KR (1) KR20090130019A (enExample)
CN (1) CN101652062A (enExample)
AU (1) AU2008223446B2 (enExample)
BR (1) BRPI0808637A2 (enExample)
CA (1) CA2680134A1 (enExample)
NZ (1) NZ579433A (enExample)
WO (1) WO2008109083A2 (enExample)
ZA (1) ZA200905954B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006322073A1 (en) 2005-12-07 2007-06-14 Hemispherx Biopharma, Inc. dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
AU2009215128A1 (en) * 2008-02-15 2009-08-20 Hemispherx Biopharma, Inc. Selective agonist of toll-like receptor 3
SI2340307T1 (sl) 2008-10-23 2016-02-29 Hemispherx Biopharma, Inc. Dvoverižne ribonukleinske kisline z robustno fizikalno-kemijsko strukturo in zelo specifično biološko aktivnostjo
US8722874B2 (en) 2008-10-23 2014-05-13 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US20100160413A1 (en) 2008-10-23 2010-06-24 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
HUE031756T2 (en) * 2008-10-31 2017-07-28 Janssen Biotech Inc TLR3 antagonists
WO2011072871A1 (en) * 2009-12-18 2011-06-23 Bavarian Nordic A/S Production of ifn-lambda by conventional dendritic cells and uses thereof
CN101780279B (zh) * 2009-12-22 2012-07-11 中山大学中山眼科中心 Toll-like receptor-3激动剂在制备促进伤口愈合的药物中的应用
WO2011130379A1 (en) * 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
ES2620748T3 (es) * 2010-06-25 2017-06-29 Idera Pharmaceuticals, Inc. Nuevos agonistas del receptor de tipo toll 3 y procedimientos de su utilización
WO2015127002A1 (en) * 2014-02-19 2015-08-27 The Johns Hopkins University Compositions and methods for promoting skin regeneration and hair growth
EP3321362A1 (en) 2016-11-10 2018-05-16 Centre Leon Berard Tlr3 agonist for use for inducing apoptosis in senescent cancer cells
MX2019007583A (es) * 2016-12-22 2019-09-04 Intervet Int Bv Vacuna de eimeria con una eficacia mejorada.
EP3833383A1 (en) 2018-08-06 2021-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers
WO2020232226A1 (en) 2019-05-16 2020-11-19 The Johns Hopkins University Compositions and methods for skin rejuvenation
US20240216364A1 (en) 2021-04-28 2024-07-04 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080726A (en) * 1985-08-12 2000-06-27 University Of Maryland Anti-viral and immuno stimulator polynucleotide duplex and use thereof
US5063209A (en) * 1985-08-26 1991-11-05 Hem Research, Inc. Modulation of aids virus-related events by double-stranded RNAs
US5683986A (en) * 1987-08-12 1997-11-04 Hemispherx Biopharma Inc. Elaboration of host defense mediators into biological fluids by systemic dsRNA treatment
IE72103B1 (en) * 1987-08-12 1997-03-12 Hem Res Inc Promotion of host defense by systemic dsRNA treatment
AU3583797A (en) * 1996-06-28 1998-01-21 Regents Of The University Of California, The Enhancement of cancer cell death
GB0119346D0 (en) * 2001-08-08 2001-10-03 Bioclones Proprietary Ltd Process for the maturation of dendritic cells
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna

Similar Documents

Publication Publication Date Title
JP2010520284A5 (enExample)
Patel et al. Novel drugs targeting Toll-like receptors for antiviral therapy
JP2011525169A5 (enExample)
Fraser et al. Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines
TWI620568B (zh) 用於治療b型肝炎及d型肝炎感染之方法
WO2008083239A3 (en) Compositions and methods for stimulating an immune response
EP4364808A3 (en) Rnai agents for hepatitis b virus infection
JP2014501762A5 (enExample)
WO2017027350A3 (en) Rnai therapy for hepatitis b virus infection
FI4023249T3 (fi) Nukleiinihapporokotteita
JP2011523653A5 (enExample)
JP2015528449A5 (enExample)
ME02893B (me) Toll-like receptor koji modulira jedinjenja 4,6-diamino-pirido[3,2-d]pirimidina
WO2009072767A3 (en) A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
WO2012055967A3 (en) Treating diabetes melitus using insulin injections administered with varying injection intervals
GR1007832B (el) Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
JP2011515490A5 (enExample)
Shakya et al. Microneedle-mediated allergen-specific immunotherapy for the treatment of airway allergy in mice
WO2009080715A3 (en) Vaccines for malaria
WO2011044570A3 (en) Recombinant antibodies against h1n1 influenza
WO2010107742A3 (en) Methods and compositions of treating a flaviviridae family viral infection
Akbar et al. A phase III clinical trial with a therapeutic vaccine containing both HBsAg and HBcAg administered via both mucosal and parenteral routes in patients with chronic hepatitis B: 923
CA2632516C (en) Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants
WO2009054708A3 (en) Antibody therapy for highly pathogenic avian influenza virus
JP2009518410A5 (enExample)